Unilever has similar problems to those Procter & Gamble faced four years ago, and now has the same activist investor on its board. But times otherwise have moved on.
Keep Reading →
May 31 - Hedge Funds, Insider Trading
Below we present the list of the top 5 healthcare stocks the experts at Sphera Global Healthcare Fund are buying.
Keep Reading →
February 20 - Hedge Funds, News
Crispin Odey’s flagship hedge fund lost money again in 2020, deepening the gloom for the bearish manager as he tries to revive his shrinking firm and fights an indecent assault...
Keep Reading →
January 6 - Hedge Funds, Insider Trading
The extended weekend is now over, and Wall Street is once again paying attention to the U.S.
Keep Reading →
May 28 - News
Fisher Investments was founded in 1979 by billionaire Ken Fisher.
Keep Reading →
November 13 - Dividend Stocks, Hedge Funds, News
Daniel Loeb's hedge fund, Third Point, has trimmed the number of nominees it is making to the Campbell Soup board to five, sources tell CNBC.
Keep Reading →
November 9 - Hedge Funds, Insider Trading
Stan Druckenmiller is a billionaire, and was the long-time manager of Duquesne Capital. Now, he oversees a family office, but his investing strategy is mostly the same.
Keep Reading →
February 24 - Hedge Funds, News
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Keep Reading →
September 23 - News
According to the American Cancer Society, more than 60,000 new cases of thyroid cancer will be diagnosed in the U.S., and about 1,850 people are expected to die from the disease...
Keep Reading →
September 23 - News
It's arguably health care's biggest name.
Keep Reading →
September 19 - News
The small patient pool for medullary thyroid cancer, or MTC, isn't going to move the needle for a large pharmaceutical company. But Exelixis, Inc.
Keep Reading →
September 17 - News
Through the years, London-based drugmaker AstraZeneca plc (ADR) (NYSE:AZN) and U.S. pharmaceutical firm Merck & Co., Inc.
Keep Reading →
September 17 - News
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Keep Reading →
September 17 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease...
Keep Reading →
September 16 - News
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
Keep Reading →
September 15 - News
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration...
Keep Reading →
September 12 - News
Investors hate to wake up and find that one of their stocks has opened nearly 30% lower than the prior day's close.
Keep Reading →
September 11 - News
I know it's like comparing apples and oranges, but humor me for a moment.
Keep Reading →
September 11 - News
Make that four collaborations between Biogen Idec Inc. (NASDAQ:BIIB) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) in the last two years.
Keep Reading →
September 10 - News
Over the past decade, the Food and Drug Administration has taken multiple steps to improve the process by which drugs are developed and eventually brought to market.
Keep Reading →
September 4 - News
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Keep Reading →
September 3 - News
The phrase "PDUFA date" is thrown around frequently when discussing biotech and pharma companies.
Keep Reading →
August 27 - News
Alkermes Plc (NASDAQ:ALKS) is primarily known for its schizophrenia and multiple sclerosis drug treatments.
Keep Reading →
August 26 - News
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
Keep Reading →
August 24 - News
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
Keep Reading →
August 20 - News
A rising tide lifts all boats, but the opposite isn't true in the stock market. The major indexes slipped this week, while a handful of health-care stocks soared.
Keep Reading →
August 17 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies.
Keep Reading →
August 12 - News
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Keep Reading →
August 12 - News
Every month, I select one or more stocks that I'll be buying in real life for my Roth IRA.
Keep Reading →
August 12 - News
As human beings it can sometimes be difficult for us to see the good in a bad situation.
Keep Reading →
August 7 - News
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been stuck is share purgatory for a number of years.
Keep Reading →
August 6 - News
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Keep Reading →
August 2 - News
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Keep Reading →
August 1 - News
Array Biopharma Inc (NASDAQ:ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market.
Keep Reading →
August 1 - News
Several companies are striving hard to manage their business and retain investors by providing an attractive dividend.
Keep Reading →
July 31 - News
The good news was that the big pharmaceutical company beat earnings estimates. Merck & Co., Inc.
Keep Reading →
July 31 - News
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) announced last week that they are making another attempt at U.S.
Keep Reading →
July 30 - News
Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year.
Keep Reading →
July 28 - News
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Keep Reading →
July 24 - News
The healthcare sector has been one of the best sectors for dividend hunters -- most of the companies operating in the sector generate massive cash flow and payout a large chunk...
Keep Reading →
July 24 - News
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co.
Keep Reading →
July 22 - News
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Keep Reading →
July 19 - News
AstraZeneca plc (ADR) (NYSE:AZN)’s financial results have been on a downward spiral lately, as patent expirations have led to sharp declines in sales of its leading drugs.
Keep Reading →
July 15 - News
"More means less." Amarin Corporation plc (ADR) (NASDAQ:AMRN) demonstrated this seemingly contradictory maxim today following its announcement of a new public offering.
Keep Reading →
July 9 - News
A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ:MDCO).
Keep Reading →
July 5 - News
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Keep Reading →
July 5 - News
A few weeks ago, CAPS player Valyooo started a lively debate with a blog entry asking for opinions on stocks vs. high-yield bonds.
Keep Reading →
July 5 - News
When screening for health-care dividend stocks, it's tempting to look for the ones with the highest yield.
Keep Reading →
July 5 - News
In the last couple of years, the biotechnology industry has been on a roll.
Keep Reading →
July 2 - News
Merck & Co., Inc. (NYSE:MRK) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth.
Keep Reading →
July 1 - News
